<DOC>
	<DOCNO>NCT00672958</DOCNO>
	<brief_summary>The purpose study determine efficacy safety daily vortioxetine ( Lu AA21004 ) adult major depressive disorder .</brief_summary>
	<brief_title>Efficacy Safety Vortioxetine ( Lu AA21004 ) Treating Adults With Major Depressive Disorder</brief_title>
	<detailed_description>The drug test study call Vortioxetine . Vortioxetine test treat depression adult major depressive disorder ( MDD ) . This study look MDD relief people take vortioxetine . The study enrol 600 patient . Participants randomly assign ( chance , like flip coin ) one two treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - Vortioxetine 5 mg - Placebo ( dummy inactive pill ) - capsule look like study drug active ingredient . All participant ask take one capsule time day throughout study . This multi-center trial conduct United States . The overall time participate study approximately 94 day . Participants make 8 visit clinic , contact telephone 1 week , 2 week , 4 week last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>Suffers major depressive episode ( MDE ) primary diagnosis accord Diagnostic Statistical Manual Mental Disorders , 4th Edition , Text Revision ( DSMIVTR ) criterion . The report duration current MDE least 3 month . Has Montgomery Åsberg Depression Rating Scale total score great equal 30 . Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . Has receive investigational compound le 30 day Screening 5 halflives prior Screening , whichever longer . Has receive Lu AA21004 previous clinical study . Has 1 follow : Any current psychiatric disorder major depressive disorder define DSMIVTR ( assess Mini International Neuropsychiatric Interview ) Current past history : manic hypomanic episode , schizophrenia , psychotic disorder , include major depression psychotic feature , mental retardation , organic mental disorder , mental disorder due general medical condition define DSMIVTR . Any substance disorder ( except nicotine caffeine ) within previous 6 month define DSMIVTR . Presence history clinically significant neurological disorder ( include epilepsy ) . Neurodegenerative disorder ( Alzheimer disease , Parkinson disease , multiple sclerosis , Huntington disease , etc ) . Any Axis II disorder might compromise study . Is required take intend continue take disallowed medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication , include : Narcotic analgesic Nonsteroidal antiinflammatory drug Rifampin Macrolide antibiotic Hormones ( thyroid hormone replacement , contraceptives [ oral , patch ] , estrogen progesterone replacement therapy allow chronic use ) Hypoglycemic agent ( chronic use allow ) Insulin ( chronic use allow ) Systemic steroid Quinidine Antineoplastics Antiobesity agent Has significant risk suicide accord investigator 's opinion score great equal 5 item 10 ( suicidal thought ) Montgomery Åsberg Depression Rating Scale make suicide attempt previous 6 month . The current depressive symptom consider investigator resistant 2 adequate antidepressant treatment least 6 week duration . Has receive electroconvulsive therapy within 6 month prior Screening . Is currently receive formal cognitive behavioral therapy , systematic psychotherapy , plan initiate therapy study . Has clinically significant unstable illness , example , hepatic impairment renal insufficiency , cardiovascular , pulmonary , gastrointestinal , endocrine , neurological , rheumatologic , immunologic , infectious , skin subcutaneous tissue disorder , metabolic disturbance . Has alanine aminotransferase , aspartate aminotransferase total bilirubin level great 1.5 time upper limit normal . Has serum creatinine great 1.5 time upper limit normal . Has previous history cancer remission le 5 year prior first dose study medication . This criterion include basal cell Stage I squamous cell carcinoma skin . Has clinically significant abnormal vital sign determine investigator . Has abnormal electrocardiogram determine central reader confirm clinically significant investigator . Has 1 laboratory value outside normal range , base blood urine sample take Screening Visit , consider investigator clinically significant . Has thyroid stimulate hormone value outside normal range Screening Visit determine clinically significant investigator . Has disease take medication , opinion investigator , could interfere assessment safety , tolerability , efficacy . Has previously enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Depression</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Major Depressive Episode</keyword>
</DOC>